# Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

> **NCT00347919** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 189 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** pazopanib (GW786034) 400 mg
- **DRUG:** lapatinib (GW572016) 1500 mg
- **DRUG:** lapatinib (GW572016) 1000 mg
- **DRUG:** pazopanib (GW786034) 800 mg

## Key facts

- **NCT ID:** NCT00347919
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-08
- **Final completion:** 2015-03
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2016-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347919, "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00347919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*